Alternatives to weekly injections of weight-loss drugs may be on the way. A monthly dose of a new drug called MariTide helped participants in a phase 2 clinical trial shed about 20% of their body weight over a year,

Amgen's long-acting experimental obesity drug MariTide needs to be given at a low starting dose to limit side effects like vomiting, according to mid-stage trial results presented at a medical meeting on Monday that pushed the company's shares down nearly 6%.